Malignant Endocrine Neoplasm — Trials

Malignant Endocrine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 576
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +2.2%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (238)

clinicaltrialsPublishedShowing 151–200 of 250 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03613597	Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer	unknown	Phase 2	118	Guizhou Medical UniversityOTHER	1	Feb 5, 2020	clinicaltrials
NCT03613753	Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer	unknown	Phase 2	72	ShengFa SuOTHER	1	Feb 5, 2020	clinicaltrials